Fundraising Fox
/Companies
Sign in

Cirrus Therapeutics

Cambridge, US · Founded 2022 · 12 employees on LinkedIn · 3 known investors

Find your way into Cirrus Therapeutics

Sign up to find every way you can get introduced to Cirrus Therapeutics

  • Your email: who you already know at Cirrus Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cirrus Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.

BiotechHealthtechLongevity

Founders & leadership

Cirrus Therapeutics was founded in 2022 by Ying Kai Chan.

YKYing Kai Chan
Ying Kai ChanCo-founder & CEOCo-founder & CEO at Cirrustx
AD
Andrew DickNamed on SEC filing

Board

ACAlexandra Cantley
Alexandra CantleyBoard MemberManaging Partner at Polaris Partners
KS
Khoo ShihBoard director

Investors · 3

ZAKA VClisted by ZAKA VCSan Francisco

How we know: ZAKA VC's portfolio page · Not right? Tell us

Polaris PartnersinferredBoston · $500K – $5Mvia Alexandra Cantley · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$6.7M disclosed across 1 round · 2025

▶$6.7MraisedAug 2025 · 8 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexandra CantleyDirector
  • Andrew DickDirector, Promoter
  • Khoo ShihDirector
  • Ying Kai ChanExecutive Officer, Director, Promoter
Offering amount
$15.7M
Amount sold
$6.7M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Cirrus Therapeutics do?
Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.
Who founded Cirrus Therapeutics?
Cirrus Therapeutics was founded by Ying Kai Chan in 2022.
Who are Cirrus Therapeutics's investors?
Cirrus Therapeutics's investors include ClavystBio, ZAKA VC, Polaris Partners.
How much funding has Cirrus Therapeutics raised?
Cirrus Therapeutics has disclosed $6.7M raised across 1 round.
Where is Cirrus Therapeutics headquartered?
Cirrus Therapeutics is headquartered in Cambridge, US.